Vaccine myocarditis evidence paper

We urge governments to remove the COVID-19 mRNA products from the market,

due to the well-documented risk of myocardial damage, a risk that is strongest for younger males (<40 years old).

Independent Medical Alliance
https://imahealth.org

Senior Fellow of Paediatric Cardiology, Dr. Kirk Milhoan

National News desk link
https://www.youtube.com/watch?v=iAdYo0EJvkU

Myocarditis after SARS-CoV-2 infection and COVID-19 vaccination: Epidemiology, outcomes, and new perspectives

International Journal of Cardiovascular Research & Innovation (OPEN ACCESS)

https://cardiovascular-research-and-innovation.reseaprojournals.com/Articles/myocarditis-after-sars-cov-2-infection-and-covid-19-vaccination-epidemiology-outcomes-and-new-perspectives

Myocarditis, typically manifesting as myopericarditis,

is among the serious cardiac consequences observed over the course of the COVID-19 pandemic.

A comprehensive, evidence-based literature synthesis

Clinical trial data reanalyses

Post-marketing surveillance

Large observational studies

Epidemiological, clinical, and immunological perspectives

Phenomenon of myocarditis post SARS-CoV-2 infection versus COVID-19 vaccine-induced myocarditis.

Conclusions refute several claims

(1). Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Omicron infections have caused more cases of myocarditis than the COVID-19 mRNA immunizations

Refuted

(2) mRNA vaccine-induced myocarditis is typically mild, transient, and rare, with no long-term sequelae

Refuted

(3) the risk-benefit calculus favors continued use of these products despite evidence of more iatrogenic (vaccine causes) cases

Refuted